The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| JANX | -51.86% | N/A | N/A | -44% |
| S&P | +21.6% | +71.83% | +11.43% | +60% |
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.
Janux's chief business officer unloaded 16.87% of his direct holdings in a routine insider sale.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$468.00K | 8.6% |
| Gross Margin | 94.99% | 111.2% |
| Market Cap | $830.04M | -73.2% |
| Market Cap / Employee | $7.62M | -81.3% |
| Employees | 109 | 34.6% |
| Net Income | -$31,946.00K | -58.0% |
| EBITDA | -$41,933.00K | -47.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $52.33M | -87.8% |
| Accounts Receivable | $7.50M | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $19.75M | -7.2% |
| Short Term Debt | $2.39M | 36.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -10.98% | -1.4% |
| Return On Invested Capital | -29.35% | -21.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$28,648.00K | -70.9% |
| Operating Free Cash Flow | -$28,542.00K | -70.7% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.56 | 1.35 | 1.46 | 0.85 | -80.11% |
| Price to Sales | 178.70 | 3257.28 | 151.59 | 85.76 | -70.16% |
| Price to Tangible Book Value | 1.56 | 1.35 | 1.46 | 0.85 | -80.11% |
| Enterprise Value to EBITDA | -19.69 | -10.23 | -15.81 | 2.07 | -102.89% |
| Return on Equity | -9.3% | -12.8% | -12.5% | -11.5% | 13.74% |
| Total Debt | $22.61M | $22.19M | $22.66M | $22.14M | -3.85% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
